Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-b3a525a247bab07c652b4fb8f5f55618"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-b3a525a247bab07c652b4fb8f5f55618"/>
<resource>
<Composition>
<id value="composition-en-b3a525a247bab07c652b4fb8f5f55618"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-b3a525a247bab07c652b4fb8f5f55618"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-b3a525a247bab07c652b4fb8f5f55618</b></p><a name="composition-en-b3a525a247bab07c652b4fb8f5f55618"> </a><a name="hccomposition-en-b3a525a247bab07c652b4fb8f5f55618"> </a><a name="composition-en-b3a525a247bab07c652b4fb8f5f55618-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/14/941/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - vizamyl</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/14/941/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpb3a525a247bab07c652b4fb8f5f55618"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - vizamyl"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What VIZAMYL is and what it is used for</li><li>What you need to know before VIZAMYL is used</li><li>How VIZAMYL is used</li><li>Possible side effects</li><li>How VIZAMYL is stored</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What vizamyl is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What vizamyl is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>VIZAMYL contains the active substance flutemetamol (18F) and is used to help diagnose Alzheimer s disease and other causes of memory loss.<br/>This medicine is a radiopharmaceutical product for diagnostic use only.</p><p>VIZAMYL is used to help diagnose Alzheimer s disease and other causes of memory loss. It is given to adults with memory problems before they undergo a type of brain scan called a positron-emission tomography (PET) scan. This scan, along with other brain function tests, can help your doctor determine whether or not you may have -amyloid plaques in your brain. -Amyloid plaques are deposits sometimes present in the brains of people with dementias (such as Alzheimer s disease).</p><p>You should discuss the results of the test with the doctor that requested the scan.</p><p>The use of VIZAMYL involves exposure to small amounts of radioactivity. Your doctor and the nuclear medicine doctor have considered that the clinical benefit of this procedure with the radiopharmaceutical outweighs the risk of being exposed to these small amounts of radiation.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take vizamyl"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take vizamyl"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>VIZAMYL must not be used:</p><ul><li>If you are allergic to flutemetamol (18F) or any of the other ingredients of this medicine (listed in section 6).</li></ul><p>Warnings and precautions Talk to your nuclear medicine doctor before you are given VIZAMYL if you:</p><ul><li>have kidney problems</li><li>have liver problems</li><li>are pregnant or think you may be pregnant</li><li>are breast-feeding</li></ul><p>Children and adolescents VIZAMYL is not intended for use in children and adolescents below the age of 18 years old.</p><p>Other medicines and VIZAMYL Tell your nuclear medicine doctor if you are taking, have recently taken or might take any other medicines since they may interfere with the images obtained from the brain scan.</p><p>Pregnancy and breast-feeding You must inform the nuclear medicine doctor before you are given VIZAMYL if there is a possibility you might be pregnant, if you have missed your period or if you are breast-feeding. When in doubt, it is important to consult the nuclear medicine doctor who will supervise the procedure.</p><p>If you are pregnant The nuclear medicine doctor will only give this medicine during pregnancy if a benefit is expected which would outweigh the risks.</p><p>If you are breast-feeding You must stop breast-feeding for 24 hours after the injection. Express the breast milk during this period and discard any breast milk you have expressed. Resuming breast-feeding should be in agreement with the nuclear medicine doctor who will supervise the procedure.</p><p>You should avoid any close contact with young children for 24 hours following the injection.</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your nuclear medicine doctor for advice before you are given this medicine.</p><p>Driving and using machines VIZAMYL may cause transient dizziness or vertigo, which may affect your ability to drive or use machines. You should not drive, use machines or engage in other potentially hazardous activities until these effects have completely disappeared.</p><p>VIZAMYL contains alcohol (ethanol) and sodium VIZAMYL contains alcohol (ethanol). Each dose contains up to 552 mg alcohol. This is about the same as 14 mL of beer or 6 mL of wine. This could be harmful for people with alcoholism and needs to be taken into account in pregnant or breast-feeding women and people with liver problems or epilepsy.</p><p>VIZAMYL contains a maximum of 41 mg of sodium (main component of cooking/table salt) in each dose. This is equivalent to approximately 2% of the adult recommended maximum daily dietary intake for sodium These amounts may need to be considered for people on a low sodium diet.</p></div>
</text>
</section>
<section>
<title value="3. How to take vizamyl"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take vizamyl"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>There are strict laws on the use, handling and disposal of radiopharmaceutical products. VIZAMYL will only be used in special controlled areas. This product will only be handled and given to you by professionals who are trained and qualified to use it safely. They will provide you with the necessary information on the procedure.</p><p>Your nuclear medicine doctor may ask you to drink plenty of water before the start of the examination and the 24 hours after the study in order to urinate as often as possible to help remove it from your body faster.</p><p>Dose The nuclear medicine doctor supervising the procedure will decide on the amount of VIZAMYL to be used in your case. The doctor will choose the smallest amount necessary.</p><p>The usual amount recommended for an adult is 185 MBq. Megabecquerel (MBq) is the unit used to measure radioactivity.</p><p>Administration of VIZAMYL and conduct of the procedure VIZAMYL is given as an injection into your vein (intravenous injection) followed by a flush of sodium chloride solution to ensure full delivery of the dose.</p><p>One injection is sufficient to carry out the scan that your doctor needs.</p><p>Duration of the procedure A brain scan is usually taken 90 minutes after VIZAMYL is given. Your nuclear medicine doctor will inform you about the usual duration of the procedure.</p><p>After administration of VIZAMYL You should avoid any close contact with young children and pregnant women for 24 hours following the injection.</p><p>The nuclear medicine doctor will inform you if you need to take any special precautions after receiving this medicine. Contact your nuclear medicine doctor if you have any questions.</p><p>If you have received more VIZAMYL than you should An overdose is unlikely since you will only receive a single dose of VIZAMYL from the nuclear medicine doctor under controlled conditions.</p><p>However, in the case of an overdose, you would receive the appropriate treatment. Treatment consists of increasing the passing of urine and stools in order to help remove radioactivity from your body.</p><p>If you have any further questions on the use of this medicine, please ask your nuclear medicine doctor who supervises the procedure.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:</p><p>Serious side effects Tell your doctor straight away, if you notice any of the following, as you may need urgent medical treatment:</p><ul><li>Allergic reactions - the signs may include swelling of your face or eyes, having pale, itchy or tight skin or having a rash, feeling short of breath, tightness in the chest, irritation in your throat or being sick. These are uncommon side effects and may affect up to 1 in 100 people.</li></ul><p>Tell your doctor straight away if you notice any of the signs above.</p><p>Other side effects include Common - may affect up to 1 in 10 people</p><ul><li><p>looking flushed</p></li><li><p>increased blood pressure Uncommon - may affect up to 1 in 100 people. You may experience the following uncommon side effects:</p></li><li><p>headache</p></li><li><p>feeling dizzy</p></li><li><p>feeling anxious</p></li><li><p>feeling sick (nausea)</p></li><li><p>chest discomfort</p></li><li><p>low blood sugar (symptoms: hunger, headache)</p></li><li><p>back pain</p></li><li><p>feeling hot or cold</p></li><li><p>increased breathing rate</p></li><li><p>pain at the injection site</p></li><li><p>heart pounding (palpitations)</p></li><li><p>pain in muscles or bones</p></li><li><p>shaking movements (tremor)</p></li><li><p>puffy and swollen skin</p></li><li><p>fever</p></li><li><p>over breathing (hyperventilation)</p></li><li><p>change in the way you taste things</p></li><li><p>a spinning feeling (vertigo)</p></li><li><p>reduced sense of touch or sensation</p></li><li><p>feeling tired or weak</p></li><li><p>inability to get or maintain an erection</p></li><li><p>indigestion, stomach ache or sore mouth</p></li><li><p>vomiting</p></li><li><p>decreased feeling or sensitivity especially in your skin or your face</p></li><li><p>increase in blood lactate dehydrogenase or neutrophils in blood tests</p></li><li><p>skin tightness</p></li></ul><p>This radiopharmaceutical will deliver low amounts of ionising radiation, which is associated with very low risk of cancer and hereditary abnormalities (passing on faulty genes).</p><p>Reporting of side effects If you get any side effects, talk to your nuclear medicine doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store vizamyl"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store vizamyl"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>You will not have to store this medicine. This medicine is stored under the responsibility of the specialist in appropriate premises. Storage of radiopharmaceuticals will be in accordance with national regulation on radioactive materials.</p><p>The following information is intended for the specialist only.</p><p>Do not use this medicine after the expiry date and time, which are stated on the label after EXP .</p><p>Do not use this medicine if you notice that the vial is damaged or the solution contains particulate matter or appears discoloured.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What VIZAMYL contains</p><ul><li>The active substance is flutemetamol (18F). Each mL of solution contains flutemetamol (18F) 400 MBq at reference date and time.</li><li>The other ingredients are sodium chloride and ethanol anhydrous, polysorbate 80, sodium dihydrogen phosphate dihydrate, disodium hydrogen phosphate dodecahydrate and water for injections, see section 2. What VIZAMYL looks like and contents of the pack</li><li>VIZAMYL is a clear, colourless to slightly yellow solution for injection.</li><li>VIZAMYL is supplied in a 10-mL or 15-mL glass vial. Each vial is stored in a container.</li><li>Not all pack sizes may be marketed.</li></ul><p>Marketing Authorisation Holder</p><p>GE Healthcare AS Nycoveien 1<br/>NO-0485 Oslo<br/>Norway</p><p>Manufacturers Advanced Accelerator Applications Molecular Imaging Italy S.r.l. Via Piero Maroncelli 47014 Meldola (FC) Italy</p><p>Advanced Accelerator Applications Molecular Imaging France SAS Technopole de l Aube 14 Rue Gustave Eiffel 10430 Rosi res-Pr s-Troyes France</p><p>Seibersdorf Labor GmbH Grundstuck. Nr. 482/2 EZ98 KG 2444 Seibersdorf Austria</p><p>Curium PET France Parc scientifique Georges Besse 180 allee Von Neumann 30000 N mes France Curium Pharma Spain, S.A.<br/>C/Manuel Bartolome Cossio 28040 Madrid Spain</p><p>Curium Italy S.R.L. Via Ripamonti 20141 Milano (MI) Italy</p><p>Advanced Accelerator Applications Molecular Imaging Iberica S.L.U.<br/>Josep Anselm Clav Esplugues de Llobregat Barcelona, 08Spain</p><p>Advanced Accelerator Applications Molecular Imaging Italy S.R.L.<br/>Via Dell Industria,<br/>86077 Pozzilli (IS) Italy</p><p>Curium Finland Oy Saukonpaadenranta 2 Helsinki, FI-00Finland</p><p>Nucleis SA All e du Six-Ao t, 8 4000 Li ge<br/>Belgium</p><p>Helmholtz-Zentrum Dresden-Rossendorf e.V. Zentrum f r Radiopharmazeutische Tumorforschung Bautzner Landstra e 01328 Dresden Germany</p><p>ITEL Telecomunicazioni S.r.l. Via Antonio Labriola Zona Industriale SNC<br/>70037, Ruvo di Puglia (BA)<br/>Italy</p><p>La Maddalena SPA Via San Lorenzo Colli, 312/D 90146 Palermo (PA) Italy</p><p>Advanced Accelerator Applications Molecular Imaging Iberica S.L.U. Hospital Clinico Universitario Virgen de la Arrixaca, Ctra. Madrid-Cartagena, sn, El Palmar, 30120 Murcia Spain This leaflet was last revised in {month YYYY}.</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpb3a525a247bab07c652b4fb8f5f55618"/>
<resource>
<MedicinalProductDefinition>
<id value="mpb3a525a247bab07c652b4fb8f5f55618"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpb3a525a247bab07c652b4fb8f5f55618"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpb3a525a247bab07c652b4fb8f5f55618</b></p><a name="mpb3a525a247bab07c652b4fb8f5f55618"> </a><a name="hcmpb3a525a247bab07c652b4fb8f5f55618"> </a><a name="mpb3a525a247bab07c652b4fb8f5f55618-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/14/941/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: VIZAMYL 400 MBq/mL solution for injection</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/14/941/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="VIZAMYL 400 MBq/mL solution for injection"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
